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This letter is a comment on a study using the lymphocyte
transformation test (LTT) for the diagnosis of active Lyme
borreliosis caused by Borrelia burgdorferi sensu lato [1]. This
LTT study reports the ﬁndings derived from a validation panel
containing 120 blood donors seronegative for Borrelia, 40
seronegative patients with autoimmune diseases, 48 healthy
seropositive controls, and 94 seropositive patients with
clinical signs of Lyme borreliosis. Furthermore, 1480 samples
were investigated with both serology (Borrelia IgG and IgM
ELISA, and western blot; Mikrogen, Munich, Germany) and the
LTT.
The study has several major shortcomings. Concerning
inclusion criteria, it was not clearly speciﬁed how the 94
patients with clinical Lyme borreliosis were deﬁned. For
example, it was not speciﬁed whether the six patients with
Bannwarth’s syndrome had spinal pleocytosis and a positive
antibody index, as required by the European case deﬁnitions
for Lyme borreliosis, and it remains unclear how it was
determined that the 34 patients with migratory arthromyalgias
were suffering from Lyme borreliosis [2]. The 160 controls for
the LTT were preselected as being seronegative for Bor-
relia-speciﬁc antibodies, and this could introduce a selection
bias, because serology and LTT results tend to correlate. The
speciﬁcity of the LTT could therefore be overestimated.
Concerning the selection criteria for the large group of 1480
patients, it is not clear what is meant by ‘clinical diagnosis of
suspected Lyme borreliosis’, among what appears to be a
mixture of protean disorders. The clinical spectrum of these
patients was not described. Concerning the methods, it is
confusing to the reader that a cut-off for a positive stimulation
index may be both >5 and >3. In the results section, the
selection of subsets in the tables numbered 2–5 was not
explained, and the numbers do not add up. For example, 592
of the 1480 patients were reported to be LTT-positive;
however, only 340 reappear in Table 3, without an explanation
of how this subset was selected. A ﬂow diagram would have
been helpful. Forty per cent of the 1480 patients suspected of
having Lyme borreliosis were LTT-positive, and 63% were
serology-positive. This is a high percentage of positive results
as compared with a series of consecutive patients suspected of
having Lyme borreliosis in Denmark, where 9.2% were found
to be IgM-positive and 3.3% IgG-positive. This indicates either
selection bias or speciﬁcity problems in the LTT and/or the
serology assay.
The main point of the article as taken from the title is the
ability of the LTT to detect active infection and the effect of
antibiotic treatment. However, owing to the study design,
evidence of active infection is lacking. Clinical features,
including follow-up and/or detection of the organism by
culture or PCR, are absent. Also, the conclusion that the
Borrelia LTT may be used for follow-up monitoring of
disseminated B. burgdorferi sensu lato infections and provide
indications for antibiotic treatment is not supported by the
study design, as this would require a prospective trial with a
control group. Thus, the LTT paper contains methodological
shortcomings with a risk of selection bias, and the study design
and the data do not support the content of the title or the
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conclusions about the diagnosis of active infection or
measurement of treatment effect. There are several issues
that need clariﬁcation in order to allow valid conclusions to be
drawn about the Borrelia LTT.
An ethics statement is missing, and the authors declare
no conﬂict of interest, but are associated with a commercial
laboratory recommending this test (http://www.imd-berlin.
de/leistungsschwerpunkte/borreliose/ltt-borrelien.html). This
website indicates that a positive LTT result may indicate a
persisting infection. However, both neurological and
microbiological European guidelines discourage the use of
LTTs, owing to insufﬁciently rigorous validation and a low
reported speciﬁcity [2–4].
The development of a biomarker for active infection with
B. burgdorferi sensu lato would be of clinical value, as antibody
detection cannot currently distinguish active infection from
immunological memory resulting from past or asymptomatic
infection. However, T-cell recognition may be inherently
indiscriminate, and problems with speciﬁcity may therefore
be hard to avoid. A recent Swedish study did not ﬁnd the
ELISPOT technique to be useful for supplementary clinical
diagnosis, with a speciﬁcity of just 82%.
The LTT study was part of a special issue entitled
‘Chronic or Late Lyme Neuroborreliosis: Present and Future’
in the Open Neurology Journal (vol. 6, 2012). However,
‘chronic Lyme borreliosis’ is a problematic concept, as
discussed elsewhere [2,5]. As an example, it is stated that
‘over 250 peer-reviewed scientiﬁc articles demonstrate the
causal association between Lyme/tick-borne disease and
mental illness’. This is contradicted by the conclusion based
on a substantial review of the literature (Final Report of the
Lyme Disease Review Panel of the Infectious Diseases
Society of America; www.idsociety.org). In the Infectious
Diseases Society of America review, it was determined that
the large number of scientiﬁc articles concerning ‘chronic
Lyme borreliosis’ were uncontrolled case observations,
which do not give convincing evidence of the persistence
of viable organisms or the effects of prolonged antibiotic
treatment. In our opinion, a causal association is not
demonstrated by this type of study.
The Bentham Open Neurology Journal is indexed in several
databases such as PubMed by the National Library of Medicine
and EMBASE. According to the journal website, peer review is
performed. However, the issues discussed above should have
been addressed by the peer review process prior to publica-
tion. It is apparent that open-access journals may have
problems with the quality of peer review, and concerns about
this issue have been raised elsewhere (e.g. in Science).
In conclusion, the clinical value of the LTT for the diagnosis
of active Lyme borreliosis was not supported the von Baehr
et al. study [1]. Critical reading of the scientiﬁc literature is
necessary, with special attention to to adequate standards of
peer review in the increasing number of open-access journals.
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